Pittenger & Anderson’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.25M Buy
1,084
+7
+0.6% +$8.26K 0.05% 165
2026
Q2
$1.29M Buy
1,077
+200
+23% +$204K 0.05% 158
2026
Q1
$807K Buy
877
+274
+45% +$278K 0.03% 173
2025
Q4
$648K Buy
603
+72
+14% +$68.8K 0.02% 186
2025
Q3
$405K Sell
531
-10
-2% -$7.44K 0.01% 198
2025
Q2
$422K Sell
541
-1
-0.2% -$777 0.02% 189
2025
Q1
$448K Sell
542
-351
-39% -$292K 0.02% 183
2024
Q4
$689K Sell
893
-392
-31% -$325K 0.03% 171
2024
Q3
$1.14M Buy
1,285
+156
+14% +$140K 0.04% 153
2024
Q2
$1.02M Buy
1,129
+185
+20% +$148K 0.04% 157
2024
Q1
$734K Buy
944
+521
+123% +$371K 0.03% 164
2023
Q4
$247K Sell
423
-82
-16% -$47.9K 0.01% 211
2023
Q3
$271K Hold
505
– – 0.01% 186
2023
Q2
$237K Buy
505
+11
+2% +$4.61K 0.01% 195
2023
Q1
$170K Hold
494
– – 0.01% 212
2022
Q4
$181K Sell
494
-86
-15% -$30.5K 0.01% 205
2022
Q3
$188K Hold
580
– – 0.01% 193
2022
Q2
$188K Hold
580
– – 0.01% 202
2022
Q1
$166K Hold
580
– – 0.01% 224
2021
Q4
$160K Buy
580
+550
+1,833% +$139K 0.01% 225
2021
Q3
$7K Hold
30
– – ﹤0.01% 375
2021
Q2
$7K Buy
30
+16
+114% +$3.21K ﹤0.01% 343
2021
Q1
$3K Buy
+14
New +$2.74K ﹤0.01% 364
2016
Q3
– Sell
-178
Closed -$14K – 374
2016
Q2
$14K Sell
178
-1,177
-87% -$88.6K ﹤0.01% 315
2016
Q1
$98K Hold
1,355
– – 0.01% 266
2015
Q4
$114K Buy
+1,355
New +$112K 0.01% 260
2013
Q3
– Sell
-12,195
Closed -$599K – 284
2013
Q2
$599K Hold
12,195
– – 0.1% 174

Other funds holding LLY

Pittenger & Anderson's LLY Position: Q3 2026 in Review

Pittenger & Anderson increased its Eli Lilly (LLY) stake by 0.65% in Q3 2026, buying an estimated $8.26K and bringing the position to 1,084 shares worth $1.25M. The position accounts for 0.05% of the portfolio, ranked #165.

Pittenger & Anderson first reported a position in LLY in Q2 2013 and has held it in 27 quarters since. The position peaked at $1.29M in Q2 2026. 4,624 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Pittenger & Anderson held 1,084 shares of Eli Lilly worth $1.25M as of Q3 2026.
  • Pittenger & Anderson bought 7 Eli Lilly shares in Q3 2026, an estimated $8.26K.
  • Eli Lilly made up 0.05% of Pittenger & Anderson's portfolio in Q3 2026, its #165 holding.
  • Pittenger & Anderson first reported a position in Eli Lilly in Q2 2013 and has held it in 27 quarters since.
  • Pittenger & Anderson's Eli Lilly position peaked at $1.29M in Q2 2026.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Pittenger & Anderson's 13F filing for Q3 2026, filed 2 Nov 2026.